Neptune Medical earns FDA clearance for its Triton 1 robotic system
AI-summarised brief · reviewed before publication
Neptune Medical Inc. received FDA clearance for its Triton 1 robotic endoscopy system, designed to enhance colonoscopy precision and control. The system, capable of full-colon navigation, aims to improve screening, surveillance, and therapeutic procedures such as EMRs and ESDs. In a first‑in‑human CARE 1 study, Triton achieved 100 % cecal intubation, a 54.2 % adenoma detection rate, and reduced endoscopist workload by 67 %. The clearance follows a $97 million Series D round and positions Triton as a potential game‑changer in colorectal cancer care.
💡 Why It Matters
- · By delivering higher detection rates and lower operator fatigue, Triton could raise colonoscopy quality standards and reduce missed precancerous lesions, directly impacting colorectal cancer outcomes.